Lately, Si et al. revealed that intravenously injected BM-MSCs could increase GLUT expression and elevate phosphorylation of insulin receptor substrate-1 (IRS-1) and AKT in the target tissues of insulin [66], delineating that MSCs are capable of alleviating insulin resistance of diabetic patients. The gene discussed is IRS1; the disease is Insulin resistance.